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Abstract
Background: Associations between lung function and non-alcoholic fatty liver disease (NAFLD) have been
reported. However, evidence from large-scale populations about the relationship is scarce. The objective of the
study was to evaluate the relationship between lung function and NAFLD in middle-aged and elderly Chinese.
Methods: A total of 1842 participants aged 40 years or older were recruited from Chongming District, Shanghai,
China. Lung function, evaluated by forced vital capacity (FVC) and forced expiratory volume in one second (FEV1)
was measured with standard spirometry. The NAFLD was evaluated by ultrasonography.
Results: The subjects with NAFLD had lower FVC (% predicted) (0.85 ± 0.26 vs. 0.90 ± 0.28, p < 0.001) and FEV1
(% predicted) (0.93 ± 0.29 vs. 0.98 ± 0.34, p < 0.001) than non-NAFLD. After adjusting for potential risk factors, the lowest
quartile of FVC (% predicted) and FEV1 (% predicted) was associated with increased prevalence of NAFLD, with the
fully adjusted odds ratio of 1.37 and 1.24 (95% confidence interval [CI] 1.18–1.97, p < 0.001, 95% CI 1.11–1.87,
p = 0.009), respectively.
Conclusions: Impaired lung function is associated with non-alcoholic fatty liver disease, independent of conventional
metabolic risk factors.
Keywords: Lung function, Non-alcoholic fatty liver disease, Chinese, Metabolic risk factors
Background
Nonalcoholic fatty liver disease (NAFLD) is character-
ized by excessive hepatic fat accumulation of patients
who have no history of alcohol abuse [1]. Recently, the
combination of overnutrition condition and less physical
activity have made NAFLD become the most common
disease of chronic liver damage, with increased preva-
lence of obesity, diabetes, and metabolic syndrome in
developed and developing counties [2]. The traditional
risk factors of NAFLD, such as central obesity, insulin
resistance, systemic inflammation, current smoking, dia-
betes, and oxidative stress, contribute to, but cannot
fully explain the increased risk of NAFLD in the general
population [3–5].
Recently, lung function parameters, estimated by
forced vital capacity (FVC) and forced expiratory volume
in one second (FEV1) were proved to be well associated
with the development of diabetes, cardiovascular disease,
inflammation process and metabolic syndrome [6–25].
NAFLD has been considered as a hepatic manifestation
of the metabolic syndrome and is associated with various
metabolic abnormalities, including hyperlipidemia, cen-
tral obesity, and type 2 diabetes [1, 26, 27]. So, reduced
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lung function may link to an increased risk of NAFLD.
In a previous study, association of reduced lung function
with NAFLD was detected among men in a health
examination program [28]. However, evidence from
large-scale populations about the relationship between
reduced lung function and NAFLD is scarce. In addition,
it is unclear whether the association can be observed in
Chinese population.
For this purpose, the aims of this study were to test the
hypotheses that reduced lung function is independently
associated with NAFLD in a cross-sectional population
study of 1,842 middle-aged and older Chinese subjects.
Methods
Study population
In 2011, China launched a national survey of Risk
Evaluation of cAncers in Chinese diabeTic Individuals: a
lONgitudinal (REACTION) study, which was conducted
among 259,657 adults, aged 40 years and older in 25
communities across mainland China, from 2011 to 2012
[29]. The data presented in this article are based on the
baseline survey of subsamples from Shanghai in eastern
China [30, 31]. All studied individuals came from the
Chongming District in Shanghai, China. There were
9930 participants who had complete information about
age; sex; smoking and alcohol consumption habits; and a
medical history including the use of medications, BMI,
and a hepatic ultrasonic examination. Participants meet-
ing the following criteria were excluded: 1) those with a
history of known liver diseases such as hepatitis, cirrho-
sis, or malignancy; 2) those with alcohol consumption
greater than 140 g/wk for men and 70 g/wk for women.
Thus, a total of 8850 participants were eventually in-
cluded in this analysis. Of these, two communities par-
ticipants received lung function test. 1,842 participants
were eventually included in the analysis. The protocol
was approved by the Institutional Review Board of
Xinhua Hospital affiliated with Shanghai Jiao-Tong
University School of Medicine.
Data collection
A standardized questionnaire was used by trained physi-
cians to collect information such as age; sex; current smok-
ing (yes/no); current drinker (yes/no). Physical activity level
was classified as low, moderate, or high according to the
International Physical Activity Questionnaire scoring
protocol. According to participants’ responses to the corre-
sponding questions, family history of diabetes was classi-
fied as yes or no.
The details of anthropometric measurements including
height, weight, waist circumference, hip circumference
were carried by trained physicians. Blood pressure was
measured at the right arm with an automated electronic
device (OMRON Model1 Plus; Omron Company, Kyoto,
Japan) three times consecutively with 1 min intervals
after at least 5 min rest in the seated position; the three
readings were averaged for analysis. Body mass index
(BMI) was calculated as weight in kilograms divided by
the square of height in meters.
All subjects were assessed after overnight fasting for at
least 10 h, Overnight fasting and 2 h OGTT (Oral
Glucose Tolerance Test) 75 g glucose blood samples
were collected in tubes containing EDTA and were cen-
trifuged at 4 °C and stored at−80 °C until analysis. The
fasting glucose, glucose 2 h after oral glucose tolerance
test, total cholesterol (TC), triglycerides, low-density
lipoprotein (LDL) cholesterol and high-density lipopro-
tein (HDL) cholesterol were measured on an automatic
analyzer (Hitachi 7080; Tokyo, Japan). Fasting insulin
was determined by RIA (Linco Research, St. Charles,
MO). The homeostasis model assessment of insulin re-
sistance (HOMA-IR) was calculated according to the
equation described by Matthews et al. [32].
Definition of NAFLD
Hepatic ultrasonic examination was performed on all
participants by two trained ultrasonographists who were
blinded to the clinical and laboratory data, using a high-
resolution B-mode tomographic ultrasound system
(Esaote Biomedica SpA, Italy) with a 3.5-MHz probe.
Diagnosis of fatty liver by ultrasonography was defined
by the presence of at least two of three abnormal
Fig. 1 The levels of FVC (% pred) and FEV1 (% pred) in subjects with
NAFLD and without NAFLD. Data are shown as means ± SE after
adjustment for age and sex. (A for FVC and B for FEV1)
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findings: diffusely increased echogenicity of the liver
relative to the kidney, ultrasound beam attenuation, and
poor visualization of intrahepatic structures. NAFLD
was diagnosed by hepatic ultrasound after the exclusion
of alcohol abuse and other liver diseases.
Lung function measurements
Lung function tests including FVC and FEV1 were
conducted by a trained physician using Electronic
Spirometer (Model BF-II, Jintan, China). Each par-
ticipant received at least two tests (with acceptable
maneuvers) at a seated position and with nose clips in
place. The predicted values for FVC and FEV1 were
calculated from the following equations obtained in a
representative sample of Chinese population [25].
Predicted FVC of man = −4.33058–(0.01326× age
[years]) + (0.04669× height [cm]) + (0.01664× weight [kg]).
Predicted FVC of woman = −4.79287– (0.01326× age
[years]) + (0.04669× height [cm]) + (0.01664× weight [kg]).
Predicted FEV1 of man = −3.65523– (0.01850× age
[years]) + (0.04283× height [cm]) + (0.009228832× weight
[kg]).
Predicted FEV1 of woman = −4.04947– (0.01850× age
[years]) + (0.04283× height [cm]) + (0.009228832× weight
[kg]).
The percentage of predicted values for FEV1, FEV1 (%
pred), equals to FEV1 devided by the predicted values of
FEV1. The percentage of predicted values for FVC, FVC
(% pred), equals to FVC divided by the predicted values
of FVC. The ratio of FEV1 to FVC was calculated.
Statistical analysis
Normally distributed data were expressed as means ± SD,
whereas variables with a skewed distribution were reported
as median (interquartile range) and log transformed to
approximate normality before analysis. Comparisons of
means and proportions were performed with the standard
normal z and χ2 tests, respectively. Multivariate logistic re-
gression models were used to estimate the odds ratios
(ORs) for NAFLD. Potential confounding variables includ-
ing age, gender, current smoking, family history of diabetes,
systolic blood pressure, diastolic blood pressure, fasting
plasma glucose, 2 h OGTT plasma glucose, hemoglobin
A1c, waist circumference, BMI, HOMA-IR, TG, TC, LDL-c
and HDL-c were controlled in the regression models. All
statistical analysis were performed with the SPSS Statistical
Package (version 13.0; SPSS Inc., Chicago, IL). P < 0.05 was
considered statistically significant.
Results
Characteristics of participants according to FVC (% pred)
or FEV1 (% pred) quartile
Mean values of FVC (% pred), FEV1 (% pred) in subjects
with NAFLD were significantly lower than in those without
(0.85 ± 0.26 vs. 0.90 ± 0.28, 0.93 ± 0.29 vs. 0.98 ± 0.34; both
p < 0.001) (Fig. 1). Individuals with NAFLD were elder,
more likely to be metabolic syndrome, current drinker, and
heavy smoking, and had higher levels of BMI, SBP, DBP,
waist circumference, hip circumference, waist-hip ratio,
fasting plasma glucose FPG, postprandial 2-h plasma glu-
cose, A1C, HOMA-IR, TG, TC, LDL-c, AST, ALT and
GGT (all p values < 0.001), and had lower levels of
HDL-c (p < 0.001) (Table 1).
When analyzed by quartiles of FVC (% pred) or FEV1
(% pred) levels, as summarized in Tables 2 and 3, the sub-
jects with lower FVC (% pred) or FEV1 (% pred) were
more likely to be more metabolic syndrome (p < 0.001),
more smoker (p < 0.001), more drinker (p < 0.001), more
aged (p < 0.001), With respect to metabolic parameters,
the subjects in the higher FVC (% pred) or FEV1 (% pred)
quartiles exhibited low er levels of LDL cholesterol
Table 1 Baseline characteristics of the study participants,









Sex n (% men) 376(32.3) 213(31.4) 0.38
Age (years)b 55.38 ± 8.10 56.97 ± 7.55 <0.001
BMI (kg/m2) 23.32 ± 2.95 26.47 ± 6.33 <0.001
Currents smokers n (%) 275(23.63) 178(26.30) <0.001
SBP (mmHg) 127.49 ± 20.64 133.10 ± 20.98 <0.001
DBP (mmHg) 78.99 ± 10.53 81.77 ± 10.34 <0.001
Waist circumference (cm) 81.18 ± 10.46 89.42 ± 8.70 <0.001
Hip circumference (cm) 94.12 ± 6.06 99.05 ± 6.95 <0.001
Waist-hip ratio 0.86 ± 0.14 0.90 ± 0.07 <0.001
Fasting plasma glucose
(mmol/l)
6.02 ± 1.45 6.65 ± 1.93 <0.001
2 h PG (mmol/L) 7.87 ± 3.40 9.17 ± 4.22 <0.001
A1C(%) 5.82 ± 0.86 6.25 ± 1.14 <0.001
HOMA-IR 1.47 (1.13–1.92) 2.36 (1.63–3.27) <0.001
Triglycerides (mmol/l) 1.38 ± 0.95 2.16 ± 1.54 <0.001
HDL-cholesterol (mmol/l) 1.29 ± 0.33 1.15 ± 0.28 <0.001
LDL-cholesterol (mmol/l) 2.55 ± 0.74 2.70 ± 0.80 <0.001
AST(units/l) 15.92 ± 8.67 22.29 ± 12.54 <0.001
ALT(units/l) 14.15 ± 10.03 21.19 ± 15.87 <0.001
GGT(units/l) 24.09 ± 28.30 38.61 ± 48.45 <0.001
SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass
index; 2hPG postprandial 2-h plasma glucose, HbA1C Glycated hemoglobin,
LDL Low-density lipoprotein, HDL high–density lipoprotein, ALT Alanine
aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyltransferase
aData are presented as mean ± SD, median (interquartile range), or number
(percent); P value was calculated after adjustment for age, gender
bNot adjusted for itself
cThis variables was log transformed before analysis
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(p < 0.001). However, elevated FVC (% pred) or FEV1
(% pred) levels showed no association with the regu-
lar exerciser (p > 0.05).
Association between quartiles of FVC (% pred) and FEV1
(% pred) and NAFLD
As shown in Table 4, the lowest quartile of FVC (% pred)
and FEV1 (% pred) was associated with increased odds of
NAFLD, with age- and sex-adjusted odds ratio (OR) of
1.82 and 1.74, respectively (95% confidential interval (CI),
1.38–2.39 and 95% CI, 1.32–2.28; both p < 0.001). Further
adjustments for current smoking, family history of dia-
betes systolic blood pressure, diastolic blood pressure,
fasting plasma glucose, 2 h OGTT plasma glucose,
Hemoglobin A1c, waist circumference, BMI, HOMA-IR,
TG, TC, LDL-c and HDL-c did not eliminate the
associations (OR, 1.37, 95% CI, 1.18–1.97, p < 0.001 and
OR,1.24, 95% CI, 1.11–1.87, p = 0.009).
Discussion
In the present study, we found that impaired lung func-
tion as measured by FVC and FEV1 was significantly
and inversely associated with prevalence of NAFLD in a
middle-aged and elderly population without chronic pul-
monary diseases after adjustment for a wide range of
variables including age, gender, current smoking, family
history of diabetes, systolic blood pressure, diastolic
blood pressure, fasting plasma glucose, 2 h OGTT
plasma glucose, hemoglobin A1c, waist circumference,
BMI, HOMA-IR and lipid profile.
Our results are consistent with previous study that re-
strictive lung function (reduced FVC and FEV1) but not
Table 2 Characteristic according to quartiles of FVC (% predicted)a
Quartile 1 (n = 450) Quartile 2 (n = 471) Quartile 3 (n = 460) Quartile 4 (n = 471) P value
FVC (% predicted) 0.63 ± 0.09 0.77 ± 0.25 0.87 ± 0.03 1.22 ± 0.28 <0.001
FEV1 (% predicted) 0.70 ± 0.18 0.86 ± 0.15 1.01 ± 0.26 1.27 ± 0.31 <0.001
FEV1/FVC ratio 0.77 ± 0.22 0.77 ± 0.22 0.76 ± 0.23 0.74 ± 0.24 <0.001
MS (n, %) 294(65.33) 271(57.53) 253(55.00) 232(49.26) <0.001
NAFLD (n, %) 193(42.89) 188(39.92) 160(34.78) 137(29.09) <0.001
Age (years)b 56.64 ± 8.23 55.65 ± 7.87 55.37 ± 7.48 56.31 ± 7.91 0.007
Male (n, %) 45(10.00) 78 (16.56) 168(36.52) 384(81.53) <0.001
Current smoking (n, %) 51(11.33) 66(14.01) 87(18.91) 166(35.24) <0.001
Current drinker (n, %) 61(13.56) 88(18.68) 86(18.70) 183(38.85) <0.001
Regular exerciser (n, %) 265(58.89) 282(59.87) 275(59.78) 284(60.29) 0.978
BMI (kg/m2) 24.82 ± 3.97 25.09 ± 3.59 24.48 ± 3.27 24.73 ± 3.34 0.102
SBP (mmHg) 137.56 ± 19.42 134.32 ± 18.82 131.51 ± 19.15 135.78 ± 18.95 <0.001
DBP (mmHg) 82.40 ± 10.44 82.16 ± 10.87 80.98 ± 9.98 82.53 ± 10.57 <0.001
WC (cm) 86.54 ± 11.48 85.76 ± 11.11 83.93 ± 10.31 84.73 ± 10.45 0.002
FPG (mmol/L) 6.54 ± 1.87 6.65 ± 2.21 6.32 ± 1.75 6.31 ± 1.36 0.011
2 h PG (mmol/L) 9.42 ± 4.23 9.43 ± 4.57 8.70 ± 4.01 8.38 ± 3.61 <0.001
A1C (%) 5.90 ± 1.10 5.94 ± 1.23 5.75 ± 1.01 5.67 ± 0.83 <0.001
HOMA-IRc 2.32(1.44–3.31) 1.84 (1.30–2.68) 1.75(1.22–2.50) 1.66(1.18–2.32) 0.029
eGFR 124.75 ± 25.25 122.57 ± 21.90 120.30 ± 19.95 114.73 ± 21.85 <0.001
Triglycerides (mmol/L)c 1.88 ± 1.27 1.76 ± 1.30 1.63 ± 1.05 1.89 ± 1.65 0.009
TC (mmol/L) 5.14 ± 0.96 5.07 ± 0.88 4.87 ± 0.85 4.86 ± 0.88 <0.001
HDL-c (mmol/L) 1.34 ± 0.32 1.36 ± 0.31 1.31 ± 0.32 1.29 ± 0.33 0.004
LDL-c (mmol/L) 2.84 ± 0.75 2.81 ± 0.74 2.73 ± 0.70 2.71 ± 0.72 <0.001
ALT (units/l) 21.37 ± 17.36 21.08 ± 15.98 19.78 ± 14.06 17.82 ± 11.15 <0.001
AST (units/l) 25.35 ± 13.05 24.28 ± 12.53 24.13 ± 10.75 22.14 ± 7.31 <0.001
GGT (units/l) 42.19 ± 42.29 36.22 ± 51.10 30.96 ± 33.42 29.91 ± 37.36 <0.001
SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, OGTT Oral Glucose Tolerance Test, FPG Fasting Plasma Glucose, 2 h PG postprandial 2-h
Plasma Glucose, HbA1C Glycated hemoglobin, LDL Low-density lipoprotein, HDL high–density lipoprotein, ALT Alanine aminotransferase, AST aspartate aminotransferase,
GGT γ-glutamyltransferase
aData are presented as mean ± SD, median (interquartile range), or number (percent); P value was calculated after adjustment for age, gender
bNot adjusted for itself
cThis variables was log transformed before analysis
Qin et al. BMC Endocrine Disorders  (2017) 17:18 Page 4 of 7
Table 3 Characteristic according to quartiles of FEV1 (% predicted)a
Quartile 1 (n = 454) Quartile 2 (n = 467) Quartile 3 (n = 464) Quartile 4 (n = 467) P value
FEV1 (%) 0.66 ± 0.11 0.83 ± 0.03 0.95 ± 0.05 1.42 ± 0.26 <0.001
FVC (%) 0.66 ± 0.14 0.79 ± 0.12 0.92 ± 0.20 1.13 ± 0.30 <0.001
FEV1/FVC ratio 73.21 ± 22.91 77.23 ± 22.01 76.63 ± 22.81 78.02 ± 22.61 <0.001
MS (n, %) 282(62.11) 273(58.46) 255(54.96) 240(51.39) <0.001
NAFLD (n, %) 200(44.05) 171(36.62) 162(34.91) 145(30.79) <0.001
Age (years)b 56.37 ± 8.22 55.51 ± 7.72 55.17 ± 8.12 56.68 ± 7.50 0.004
Male (n, %) 47(10.35) 82(17.56) 164(35.34) 382(81.80) <0.001
Current smoking (n, %) 55(12.11) 68(14.56) 87(18.75) 159(34.05) <0.001
Current drinker (n, %) 64(14.10) 90(19.27) 89(19.18) 175(37.47) <0.001
Regular exerciser (n, %) 263(57.93) 285(61.03) 272(58.62) 287(61.46) 0.872
BMI (kg/m2) 24.81 ± 3.93 24.76 ± 3.64 25.05 ± 3.42 24.74 ± 3.32 0.556
SBP (mmHg) 136.28 ± 19.26 135.84 ± 19.25 134.38 ± 18.12 133.54 ± 20.55 0.002
DBP (mmHg) 82.50 ± 10.43 82.12 ± 10.49 82.06 ± 10.36 81.90 ± 10.81 <0.001
WC (cm) 86.04 ± 11.68 85.06 ± 11.34 86.05 ± 10.27 84.70 ± 10.29 0.015
FPG (mmol/L) 6.55 ± 1.88 6.50 ± 3.64 6.48 ± 1.90 6.36 ± 1.49 0.004
2 h PG (mmol/L) 9.30 ± 4.20 9.10 ± 4.39 9.03 ± 4.09 8.47 ± 3.79 0.017
A1C(%) 5.88 ± 1.07 5.88 ± 1.14 5.83 ± 1.11 5.70 ± 0.93 0.035
HOMA-IRc 2.30(1.42–3.33) 1.79(1.28–2.63) 1.70(1.23–2.52) 1.64(1.15–2.31) 0.025
eGFR 124.85 ± 25.05 121.73 ± 21.24 119.85 ± 21.90 115.14 ± 21.27 <0.001
Triglycerides (mmol/L) 1.86 ± 1.26 1.73 ± 1.35 1.80 ± 1.38 1.77 ± 1.42 0.035
TC (mmol/L) 5.06 ± 0.93 4.95 ± 1.02 4.98 ± 0.84 4.92 ± 0.82 0.125
HDL–c (mmol/L) 1.33 ± 0.32 1.32 ± 0.30 1.32 ± 0.31 1.32 ± 0.31 0.031
LDL-c (mmol/L) 2.83 ± 0.75 2.79 ± 0.79 2.70 ± 0.67 2.69 ± 0.68 0.007
ALT(units/l) 21.22 ± 14.07 21.15 ± 14.28 19.94 ± 13.53 18.17 ± 13.09 <0.001
AST(units/l) 24.97 ± 12.85 24.31 ± 12.66 24.03 ± 11.49 22.47 ± 10.29 <0.001
GGT(units/l) 41.25 ± 37.73 38.07 ± 43.25 31.24 ± 34.71 28.99 ± 36.52 <0.001
SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, OGTT Oral Glucose Tolerance Test, FPG Fasting Plasma Glucose, 2 h PG postprandial 2-h
Plasma Glucose, HbA1C HbA1C hemoglobin A1C, eGFR estimate the glomerular filtration rate, LDL Low-density lipoprotein, HDL high–density lipoprotein, ALT Alanine
aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyltransferase
aData are presented as mean ± SD, median (interquartile range), or number (percent); P value was calculated after adjustment for age, gender
bNot adjusted for itself
cThis variables was log transformed before analysis
Table 4 Odds ratio for the non-alcoholic fatty liver disease according to quartiles of FVC (% pred) or FEV1 (% pred)
FVC(% pred)
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P value
Model 1 1.82(1.38–2.39) 1.60(1.23–2.12) 1.29(0.97–1.70) 1 <0.001
Model 2 1.65(1.27–2.24) 1.39(1.18–2.01) 1.12(0.87–1.52) 1 <0.001
Model 3 1.37(1.18–1.97) 1.19(1.08–1.82) 1.04(0.79–1.28) 1 <0.001
FEV1(% pred)
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P value
Model 1 1.74(1.32–2.28) 1.27(0.96–1.67) 1.18(0.90–1.55) 1 <0.001
Model 2 1.48(1.24–2.12) 1.13(0.89–1.48) 1.09(0.81–1.39) 1 0.004
Model 3 1.24(1.11–1.87) 1.07(0.76–1.21) 1.03(0.72–1.19) 1 0.009
Model 1, adjusted for age and sex; model 2, further adjusted for current smoking, family history of diabetes systolic blood pressure and diastolic blood pressure;
model 3, further adjusted for fasting plasma glucose, 2 h OGTT plasma glucose, Hemoglobin A1c, waist circumference, BMI, HOMA-IR, TG, TC, LDL-c and HDL-c
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obstructive pulmonary function (FEV1-to-FVC ratio) is
associated with the development of NAFLD [28]. The
underlying mechanisms relating reduced lung function
to this type of metabolic disorder remain unclear; inte-
gration of inflammatory process and metabolic pathways
in NAFLD patients may be a pivotal underlying mechan-
ism link between reduced pulmonary function and inci-
dent NAFLD. Previous studies have demonstrated that a
strong association between both restrictive and obstruct-
ive lung patterns and inflammatory markers [33, 34]. As
we best known, low-grade systemic inflammation play a
causal role in the development of NAFLD. Thus, the
inflammatory process may contribute to the association
between reduced lung function and NAFLD. However,
the measurement of inflammatory markers was absent,
limiting the ability to access the role of this factor in the
association in the present study.
In our study, we observed that the positive association
of FVC (% pred) in particular and FEV1 (% pred) with
metabolic abnormalities and components of the insulin
resistance syndrome, which is consistent with several
previous studies that have reported associations between
restrictive lung patterns with glucose metabolism and
metabolic syndrome [6–23]. Moreover, our study also
demonstrated that FVC (% pred) and FEV1 (% pred) were
associated with insulin sensitivity as measured by the
HOMA-IR. It has been well demonstrated that insulin re-
sistance plays a key role in the development of NAFLD
[35, 36]. Metabolic risk factors closely associated with
insulin resistance (BMI, glucose, waist circumference,
blood pressure, triglycerides, and HDL cholesterol) may
affect the association of FVC (% pred), FEV1 (% pred) and
NAFLD. However, our further analysis indicated that the
effects of reduced lung function on NAFLD were inde-
pendent of metabolic syndrome features.
The strengths of this study include the community-
based sample, standardized spirometric techniques,
extensive data on potential confounders, and a large
sample size that increased precision and permitted mul-
tiple statistical adjustments. However, several limitations
of our study have to be addressed. First, due to the
cross-sectional nature of the current study, no causal
inference can be drawn. Prospective studies are needed
to clarify their precise interrelationship. Also, it has yet
to be seen whether our results in middle-aged and older
Chinese subjects can be generalized to younger popula-
tions or other ethnic groups. Secondly, liver biopsies, the
best diagnostic tool for confirming NAFLD, were not
available in our participants. The diagnosis of NAFLD
was based on ultrasonic examination, which is not sensi-
tive enough to detect mild steatosis. However, this
method is the most widely used noninvasive technique
to detect fatty infiltration of the liver in clinical practice
and epidemiological studies, and it has been reported to
have a sensitivity of 89% and specificity of 93% for the
identification of fatty liver [37]. Third, the lack of
inflammatory markers, which precluded more detailed
investigations of the causal pathway. Furthermore, sleep
duration/quality and symptoms of sleep apnea which
was related to both insulin resistance and lung function
may affect the association of impaired lung function and
NAFLD, however, due to study design defect, we
couldn’t further analyze the effect in this study.
Conclusions
We have found that impaired lung function was associ-
ated with NAFLD in middle-aged and elderly Chinese
population. These findings suggest the need to screen
impaired of lung function in people without respiratory
disease for the presence of NAFLD.
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